HOME >> BIOLOGY >> NEWS
Looking for new approaches to target antibiotic-resistant bacteria

Infection with Entercoccus faecalis can cause bacterial endocarditis, an infection of the heart valves that if not treated with antibiotics results in death. The number of infections with antibiotic-resistant E. faecalis is increasing. So, researchers are looking for alternative strategies for treating individuals who become infected with this bacterium. Now, in a study appearing in the October issue of the Journal of Clinical Investigation, researchers from University of Texas Medical School at Houston have identified proteins that are required for E. faecalis to cause endocarditis in rats and that might make good vaccine candidates.

Barbara Murray and colleagues found that E. faecalis expresses four proteins that are required for the bacteria to form protein structures on their surface known as pili. The pili were required for the bacteria to aggregate and form biofilms. More importantly, rats infected with E. faecalis lacking expression of any one of these proteins suffered less severe bacterial endocarditis. This study, identifying E. faecalis proteins required for the bacterium to cause endocarditis in rats, might lead to the development of new strategies to treat individuals who become infected with E. faecalis.

In an accompanying commentary, Jonathan Budzik and Olaf Schneewind from the University of Chicago agree with this suggestion when they comment that, "This information may enable new vaccine strategies for the prevention of E. faecalis infections."


'"/>

Contact: Karen Honey
212-342-4159
Journal of Clinical Investigation
2-Oct-2006


Page: 1

Related biology news :

1. Looking for life on Jupiters icy moon Europa
2. Looking to a new era in bee research
3. Looking for consensus on how to manage metastatic breast cancer
4. Cold case: Looking for life on Mars
5. Looking at Eyeless from two directions
6. Hydrology, Politics, and Katrina: Looking Backward, and Going Forward
7. Looking for the genes that affect a persons level of response to alcohol
8. Looking at autoimmune diabetes, literally
9. New approaches to endometriosis treatment -- mouse experiments point the way
10. New understanding of schizophrenia could lead to new treatment approaches
11. Novel approaches to tackling obesity, cancer and MRSA

Post Your Comments:
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: